ORIGINAL RESEARCH article
Front. Vet. Sci.
Sec. Anesthesiology and Animal Pain Management
Volume 12 - 2025 | doi: 10.3389/fvets.2025.1561793
This article is part of the Research TopicInnovations in Immunometabolic Treatment and Controlled Release Systems for Bone and Joint DisordersView all 6 articles
Efficacy of a joint supplement containing eggshell membrane among other ingredients to improve the mobility of dogs with osteoarthritis: a multicenter double-blind randomized placebo-controlled study
Provisionally accepted- 1Centre Hospitalier Vétérinaire Frégis, Gentilly, France
- 2Arrábida Veterinary Hospital, Arrábida Animal Rehabilitation Center, Azeitão, Portugal
- 3Faculty of Veterinary Medicine, Lusofona University, Lisboa, Lisbon, Portugal
- 4Superior School of Health, Protection and Animal Welfare, Polytechnic Institute of Lusophony, Lisbon, Portugal, Lisbon, Portugal
- 5Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca, Cluj Napoca, Cluj, Romania
- 6Clinica Veterinaria Vezzoni, Cremona, Italy
- 7Virbac SA, MU petfood petcare, Carros, France, Carros, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The management of osteoarthritis (OA) in dogs is typically multimodal, including weight management, activity adjustment, joint supplements, and medical treatments when needed. This study evaluated the efficacy of a joint supplement containing eggshell membrane, krill meal with omega-3 fatty acids, Haematococcus pluvialis as a source of astaxanthin, hyaluronic acid and a Boswellia Serrata extract, in dogs with OA, in a multicenter, randomized, placebo-controlled trial. Fifty-two dogs with confirmed OA were given the test supplement or a placebo, for 90 days. Owners regularly completed two validated questionnaires for osteoarthritis (CBPI and LOAD) and rated their dog's discomfort every 15 to 30 days. Monthly evaluations by investigators included assessments of the dog's posture, gait, joint pain upon palpation and range of motion (from 1-normal to 4-severe or severely impacted) to determine a clinical score. Statistical analyses included both within-group and between-group comparisons. Of the 52 dogs enrolled, 46 completed the study, with 22 receiving the supplement and 24 receiving the placebo. All main parameters significantly improved over time in the supplement group (CBPI pain severity, CBPI pain interference, LOAD, discomfort, clinical score). In the placebo group, only the CBPI pain interference and LOAD improved. However, there was a statistically significant difference between groups for the CBPI pain interference (p=0.009).Therefore, this study demonstrates that the test supplement can improve the mobility and quality of life of osteoarthritic dogs.
Keywords: Mobility issues, Joint disorder, nutraceutical, Canine osteoarthritis, Movoflex, Pain, Movement, mobility improvement
Received: 16 Jan 2025; Accepted: 24 Apr 2025.
Copyright: © 2025 Ragetly, Martins, Ober, Boiocchi and Nicolas. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Céline S Nicolas, Virbac SA, MU petfood petcare, Carros, France, Carros, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.